Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE.
CENTRAX vs CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
10-30 mg orally, 3-4 times daily.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine